1887

oa SA Pharmaceutical Journal - Efient® (prasugrel) : a new antiplatelet agent : new product focus - drug info

Volume 79, Issue 1
  • ISSN : 2221-5875

 

Abstract

Efient®, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of atherothrombotic events in patients with acute coronary syndromes who are undergoing percutaneous coronary intervention, as follows:

  • Patients with unstable angina or non-ST segment elevation myocardial infarction, who are managed with percutaneous coronary intervention.
  • Patients with ST-segment elevation myocardial infarction, who are managed with primary, or delayed, percutaneous coronary intervention.

Loading full text...

Full text loading...

Loading

Article metrics loading...

/content/mp_sapj/79/1/EJC82682
2012-02-01
2017-03-25

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error